Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634437 · ClinicalTrials.gov registry record · Phase 1
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02634437 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 19 participants.
The verdict
NCT02634437, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.
Interventions
- DRUG Ulipristal acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2016-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634437
The ClinicalTrials.gov registry entry for NCT02634437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ulipristal acetate is the first listed.
NCT02634437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634437 about?
NCT02634437 is a clinical study titled "Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects". This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.
What is the current status of trial NCT02634437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2015-12-01. Estimated completion is 2016-12-09.
What interventions are being tested in trial NCT02634437?
The interventions under investigation include: Ulipristal acetate (DRUG).
Who is sponsoring clinical trial NCT02634437?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.